Literature DB >> 24706440

The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.

Alessandra Gentile1, Luca Lazzari, Silvia Benvenuti, Livio Trusolino, Paolo Maria Comoglio.   

Abstract

MET is a master gene controlling a genetic program driving proliferation, apoptosis protection and invasion. The ROR1 pseudokinase acts as a MET substrate. However, its contribution to MET signaling and MET-dependent biological outcomes remains to be elucidated. By structure-function analysis of ROR1 mutants, we show that ROR1 encompasses two major substrate regions: one is located in the proline-rich domain and is directly phosphorylated by MET; the other resides in the pseudokinase domain and is phosphorylated through intermediate activation of SRC. Differential phosphorylation of these two regions dictates the execution of specific responses: phosphorylation of the ROR1 proline-rich domain by MET-but not phosphorylation of the pseudokinase domain by SRC-is necessary and sufficient to control MET-driven proliferation and protection from apoptosis. Differently, both the proline-rich and the pseudokinase domains mediate cell invasion. Consistent with the role of ROR1 in specifying the functional consequences of MET-dependent signals, ROR1 silencing leads to selective attenuation of only some of the signal transduction pathways sustained by MET. These data enlighten the so far elusive function(s) of pseudokinases and identify a mechanism of biological diversification, based on substrate specificity of oncogenic kinases.
© 2014 UICC.

Entities:  

Keywords:  RTK; oncogene addiction; pseudokinase; receptor tyrosine kinase; transphosphorylation

Mesh:

Substances:

Year:  2014        PMID: 24706440     DOI: 10.1002/ijc.28879

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

Review 1.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Authors:  Michael Y Choi; George F Widhopf; Christina C N Wu; Bing Cui; Fitzgerald Lao; Anil Sadarangani; Joy Cavagnaro; Charles Prussak; Dennis A Carson; Catriona Jamieson; Thomas J Kipps
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

2.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

3.  Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.

Authors:  Joshua B Sheetz; Sebastian Mathea; Hanna Karvonen; Ketan Malhotra; Deep Chatterjee; Wilhelmiina Niininen; Robert Perttilä; Franziska Preuss; Krishna Suresh; Steven E Stayrook; Yuko Tsutsui; Ravi Radhakrishnan; Daniela Ungureanu; Stefan Knapp; Mark A Lemmon
Journal:  Mol Cell       Date:  2020-07-02       Impact factor: 17.970

Review 4.  State of the structure address on MET receptor activation by HGF.

Authors:  Edmond M Linossi; Gabriella O Estevam; Masaya Oshima; James S Fraser; Eric A Collisson; Natalia Jura
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

5.  Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.

Authors:  Yanchun Liu; Hui Yang; Tianxing Chen; Yongbin Luo; Zheyuan Xu; Ying Li; Jiahui Yang
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 6.  Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Int J Mol Sci       Date:  2014-08-08       Impact factor: 5.923

7.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

8.  Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Authors:  C E Henry; C Emmanuel; N Lambie; C Loo; B Kan; C J Kennedy; A de Fazio; N F Hacker; C E Ford
Journal:  Transl Oncol       Date:  2017-03-23       Impact factor: 4.243

9.  miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.

Authors:  Jinqiu Tao; Xiaofei Zhi; Xiaoyu Zhang; Min Fu; Hao Huang; Yu Fan; Wenxian Guan; Chen Zou
Journal:  J Exp Clin Cancer Res       Date:  2015-11-14

10.  Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis.

Authors:  Claire Henry; Neville Hacker; Caroline Ford
Journal:  Oncotarget       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.